Status:
COMPLETED
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
COVID-19 by SARS-CoV-2 Infection
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
SARS-CoV-2 induces over-production of inflammatory cytokines, and especially interleukin-6 (IL-6). The apparently strong association between blood levels of inflammaory cytokines and SARS-CoV-2 diseas...
Eligibility Criteria
Inclusion
- Patients with end-stage chronic renal disease requiring haemodialysis support;
- SARS-CoV-2 positive (RT-PCR);
- COVID-19 symptoms at least once over a 8-day period preceding inclusion;
- Hospitalized or outpatients in one of the study centers: CHU de Nice, CHU de Strasbourg, Hôpital Necker (APHP), Hôpital Kremlin Bicêtre (APHP), Hôpital Pitié-Salpétriêre (APHP), Hospices Civils de Lyon, CHU de Saint-Etienne, CHU de Montpellier, Hôpital La Conception (APHM);
- Age \> 18 years;
- Free and informed consent.
Exclusion
- Age \> 85 years ;
- Peritoneal dialysis;
- Onset of symptoms (fever and/or cough) for more than 8 days;
- Acute respiraytory distress despite oxygen therapy, 02 ≥ 4L/min, arterial pressure \< 85/55 mmHg or hemodynamic instability at time of inclusion, encephalopathy with Glasgow coma scale \< 14;
- Treatment with non-steroids anti-inflammatory agents within the laste 14 days preceding onset of symptoms;
- Active bacterial or fungal infection documented at inclusion;
- Pregnancy;
- Under guardianship or curatorship;
- Non-affiliated person with Social Security.
Key Trial Info
Start Date :
May 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 27 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04371510
Start Date
May 20 2020
End Date
August 27 2021
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de nice
Nice, Alpes-Maritimes, France, 06001